222 related articles for article (PubMed ID: 21617354)
1. Benzyldihydroxyoctenone, a novel nonsteroidal antiandrogen, shows differential apoptotic induction in prostate cancer cells in response to their androgen responsiveness.
Suh H; Oh HL; Lee CH
J Microbiol Biotechnol; 2011 May; 21(5):540-4. PubMed ID: 21617354
[TBL] [Abstract][Full Text] [Related]
2. Benzyldihydroxyoctenone, a novel anticancer agent, induces apoptosis via mitochondrial-mediated pathway in androgen-sensitive LNCaP prostate cancer cells.
Moon HS; Lim H; Moon S; Oh HL; Kim YT; Kim MK; Lee CH
Bioorg Med Chem Lett; 2009 Feb; 19(3):742-4. PubMed ID: 19119006
[TBL] [Abstract][Full Text] [Related]
3. 6-(3,4-Dihydro-1H-isoquinoline-2-yl)-N-(6-methoxypyridine-2-yl) nicotinamide-26 (DIMN-26) decreases cell proliferation by induction of apoptosis and downregulation of androgen receptor signaling in human prostate cancer cells.
Choi HE; Shin JS; Leem DG; Kim SD; Cho WJ; Lee KT
Chem Biol Interact; 2016 Dec; 260():196-207. PubMed ID: 27720946
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological inhibition of androgen receptor expression induces cell death in prostate cancer cells.
Song IS; Jeong YJ; Kim J; Seo KH; Baek NI; Kim Y; Kim CS; Jang SW
Cell Mol Life Sci; 2020 Nov; 77(22):4663-4673. PubMed ID: 31894360
[TBL] [Abstract][Full Text] [Related]
5. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
Koochekpour S; Lee TJ; Wang R; Culig Z; Delorme N; Caffey S; Marrero L; Aguirre J
Prostate; 2007 Feb; 67(2):178-89. PubMed ID: 17044040
[TBL] [Abstract][Full Text] [Related]
6. Combination of resveratrol and antiandrogen flutamide has synergistic effect on androgen receptor inhibition in prostate cancer cells.
Kai L; Levenson AS
Anticancer Res; 2011 Oct; 31(10):3323-30. PubMed ID: 21965742
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of androgen receptor by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells.
Bhuiyan MM; Li Y; Banerjee S; Ahmed F; Wang Z; Ali S; Sarkar FH
Cancer Res; 2006 Oct; 66(20):10064-72. PubMed ID: 17047070
[TBL] [Abstract][Full Text] [Related]
8. Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.
Wang Y; Liu G; Tong D; Parmar H; Hasenmayer D; Yuan W; Zhang D; Jiang J
Prostate; 2015 Aug; 75(11):1187-96. PubMed ID: 25894097
[TBL] [Abstract][Full Text] [Related]
9. Capillarisin blocks prostate-specific antigen expression on activation of androgen receptor in prostate carcinoma cells.
Tsui KH; Chang YL; Feng TH; Hou CP; Lin YH; Yang PS; Lee BW; Juang HH
Prostate; 2018 Mar; 78(4):242-249. PubMed ID: 29164633
[TBL] [Abstract][Full Text] [Related]
10. A novel regulation of PSMA and PSA expression by Q640X AR in 22Rv1 and LNCaP prostate cancer cells.
Ben Jemaa A; Sallami S; Céraline J; Oueslati R
Cell Biol Int; 2013 May; 37(5):464-70. PubMed ID: 23418075
[TBL] [Abstract][Full Text] [Related]
11. HY251, a novel decahydrocyclopenta[a]indene analog, from Aralia continentalis induces apoptosis via down-regulation of AR expression in human prostate cancer LNCaP cells.
Oh HL; Lee CH
Bioorg Med Chem Lett; 2011 Mar; 21(5):1347-9. PubMed ID: 21315590
[TBL] [Abstract][Full Text] [Related]
12. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.
Tepper CG; Vinall RL; Wee CB; Xue L; Shi XB; Burich R; Mack PC; de Vere White RW
Prostate; 2007 Apr; 67(5):521-35. PubMed ID: 17252539
[TBL] [Abstract][Full Text] [Related]
13. Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells.
Bhattacharyya RS; Krishnan AV; Swami S; Feldman D
Mol Cancer Ther; 2006 Jun; 5(6):1539-49. PubMed ID: 16818513
[TBL] [Abstract][Full Text] [Related]
14. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
[TBL] [Abstract][Full Text] [Related]
15. Effects of a novel carbocyclic analog of pyrrolo[2,3-d]pyrimidine nucleoside on pleiotropic induction of cell death in prostate cancer cells with different androgen responsiveness.
Suh H; Choi KW; Lee J; Ryou C; Rhee H; Lee CH
Bioorg Med Chem Lett; 2016 Feb; 26(4):1130-5. PubMed ID: 26832220
[TBL] [Abstract][Full Text] [Related]
16. [Effect of compound Chinese traditional medicine PC-SPES II in inhibiting proliferation of human prostate cancer cell LNCaP and on expressions of AR and PSA].
Zhang BY; Li YF; Lai Y; Li YS; Chen ZJ
Zhongguo Zhong Yao Za Zhi; 2015 Mar; 40(5):950-6. PubMed ID: 26087562
[TBL] [Abstract][Full Text] [Related]
17. Androgenic up-regulation of androgen receptor cDNA expression in androgen-independent prostate cancer cells.
Dai JL; Maiorino CA; Gkonos PJ; Burnstein KL
Steroids; 1996 Sep; 61(9):531-9. PubMed ID: 8883219
[TBL] [Abstract][Full Text] [Related]
18. Difference in protein expression profile and chemotherapy drugs response of different progression stages of LNCaP sublines and other human prostate cancer cells.
Lin HP; Lin CY; Hsiao PH; Wang HD; Jiang SS; Hsu JM; Jim WT; Chen M; Kung HJ; Chuu CP
PLoS One; 2013; 8(12):e82625. PubMed ID: 24349321
[TBL] [Abstract][Full Text] [Related]
19. Indole-3-carbinol inhibition of androgen receptor expression and downregulation of androgen responsiveness in human prostate cancer cells.
Hsu JC; Zhang J; Dev A; Wing A; Bjeldanes LF; Firestone GL
Carcinogenesis; 2005 Nov; 26(11):1896-904. PubMed ID: 15958518
[TBL] [Abstract][Full Text] [Related]
20. Establishment and characterization of androgen-independent human prostate cancer cell lines, LN-REC4 and LNCaP-SF, from LNCaP.
Iwasa Y; Mizokami A; Miwa S; Koshida K; Namiki M
Int J Urol; 2007 Mar; 14(3):233-9. PubMed ID: 17430262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
